Radiopharmaceutical and methods
The radiopharmaceutical 177 Lu-PSMA I&T is provided, including in high purities with extended shelf life. Further provided are methods of synthesis of 177 Lu-PSMA I&T and pharmaceutical compositions and methods of treatment that comprise 177 Lu-PSMA I&T.
1. An aqueous single dosage pharmaceutical composition suitable for delivery of at least 6.8 GBq+/−10% 177 Lu-PSMA I&T to a patient, comprising:
(a) a complex of lutetium-177 and EuK-Sub-kf-iodo-y-DOTAGA having 99% or greater lutetium-177 incorporation as determined by radio-iTLC;
(b) one or more ascorbate compounds at a concentration of at least 50 mg/mL, and
(c) one or more gentisate compounds at a concentration of at least 15 mg/mL;
wherein the pharmaceutical composition has a volumetric radioactivity of 250 to 1200 MBq/mL and maintains a radiochemical purity of 95% or greater as determined by radio-HPLC after 3 days at 30° C. so as to maintain a dose of at least 6.8 GBq+/−10% 177 Lu-PSMA I&T at day 3.
2. The composition of claim 1 wherein the radiochemical purity of the pharmaceutical composition is at least 95% at a temperature of 30° C. for 5 days following preparation of the composition so as to maintain a dose of at least 6.8 GBq+/−10% 177 Lu-PSMA I&T at day 5.
3. The composition of claim 1 wherein the one or more ascorbate compounds are present in an amount of from 55 mg/mL to 75 mg/mL of the pharmaceutical composition.
4. The composition of claim 1 wherein the one or more gentisate compounds are present in an amount of from 16 mg/mL to 36 mg/mL of the pharmaceutical composition.
5. The composition of claim 3 wherein the one or more gentisate compounds are present in an amount of from 16 mg/mL to 36 mg/mL of the pharmaceutical composition.
6. The composition of claim 1 , contained in a single-dose vial or syringe at volume of 10 to 14 mL.
7. The composition of claim 1 , further including diethylentriaminepentaacetic acid (DTPA) in a concentration of from 0.01 to 0.50 mg/mL.
8. A pharmaceutical composition comprising:
(a) a complex of lutetium-177 and EuK-Sub-kf-iodo-y-DOTAGA, which complex is generated by an incorporation reaction, comprising;
(i) combining lutetium-177 and EuK-Sub-kf-iodo-y-DOTAGA in a reaction buffer having a final concentration of one or more ascorbate compounds of 55 mg/mL or greater, but in the absence of gentisic acid; and
(ii) heating the reaction composition to a temperature no greater than 90° C. to form the complex, which complex has 99% or greater lutetium-177 incorporation as determined by radio-iTLC;
(b) one or more ascorbate compounds present in a total amount of from 50 mg/mL to 100 mg/mL of the pharmaceutical composition; and
(c) one or more gentisate compounds present in a total amount of from 15 mg/mL or more of the pharmaceutical composition;
wherein the complex formed in step (a), after being formed and cooled, is admixed with the ascorbate and gentisate compounds and brought to a volume such that the resulting pharmaceutical composition has a volumetric radioactivity of 250 to 1200 MBq/mL, and the radiochemical purity of the pharmaceutical composition is at least 95% as determined by radio-HPLC at a temperature of 30° C. for 3 days following preparation of the composition.
9. The composition of claim 8 wherein the radiochemical purity of the pharmaceutical composition is at least 95% at a temperature of 30° C. for 5 days following preparation of the composition.
10. The composition of claim 8 wherein the one or more ascorbate compounds are present in an amount of from 55 mg/mL to 75 mg/mL of the pharmaceutical composition.
11. The composition of claim 8 wherein the one or more gentisate compounds are present in an amount of from 16 mg/mL to 36 mg/mL of the pharmaceutical composition.
12. The composition of claim 10 wherein the one or more gentisate compounds are present in an amount of from 16 mg/mL to 36 mg/mL of the pharmaceutical composition.